Eylea Use In Pregnancy & Lactation

Women of childbearing potential: Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see Precautions).
Pregnancy: There are no data on the use of aflibercept in pregnant women.
Studies in animals have shown embryo-foetal toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Although the systemic exposure after ocular administration is very low, Eylea should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.
Breast-feeding: It is unknown whether aflibercept is excreted in human milk. A risk to the breast-fed child cannot be excluded.
Eylea is not recommended during breast-feeding. A decision must be made whether to discontinue breast-feeding or to abstain from Eylea therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: Results from animal studies with high systemic exposure indicate that aflibercept can impair male and female fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions). Such effects are not expected after ocular administration with very low systemic exposure.